Metrics as of 10/13/2026, 06:51 PM (Berlin time), refresh in progress.
Upstream Bio Stock
Upstream Bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- E. Rand Sutherland
- Employees
- 75
- Market cap
- $193 M
- IPO
- 11/10/2024
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the…
Upstream Bio stock: price history
1D
-14.9%
1W
-22.7%
1M
-38.0%
6M
-65.7%
YTD
-86.9%
1Y
-82.3%
2Y
-83.9%
5Y
–
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~31% weaker price swings than usual
Ask the agents about Upstream Bio
Analyst assessment of Upstream Bio
PRICE TARGET LOW
US$25.00
CONSENSUS
US$25.00
MEDIAN
US$25.00
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
3
BUY
2
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 02/09/2026
Upstream Bio stock metrics
P/E
-1.22
P/B
0.71
EV/EBITDA
-0.73
RETURN ON EQUITY
-14.7%
NET MARGIN
-5,136.1%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
36.9%
FLOAT SHARES
20,083,581
AVG. DAILY VOLUME (30D)
796,646
Insider transactions (SEC)
Deykin Aaron
Ambrose Allison
GRAY MICHAEL
Houghton Adam
Sutherland Everett Rand
Institutional holders
Comparable stocks
Frequently asked questions about Upstream Bio stock
What does Upstream Bio do?
Upstream Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is E. Rand Sutherland, the company employs around 75 people.
The IPO was on 11/10/2024; the stock trades on NASDAQ under the ticker UPB.
What do analysts say about Upstream Bio stock?
5 analysts rate the stock, the consensus is Buy (as of 02/09/2026).
The average price target is US$25.00, ranging from US$25.00 to US$25.00, with a median of US$25.00.
This is an external assessment, not a statement by Market Jury.
When does Upstream Bio report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -31% stronger than usual.
Does Upstream Bio pay a dividend?
No, Upstream Bio currently does not pay a dividend.
Which stocks are comparable to Upstream Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Upstream Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Upstream Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.